UNITED STATES OMB APPROVAL
 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB Number:

Expires:

3235-0058

April 30, 2025

    Estimated average burden hours
    per response 2.50
 

FORM 12b-25

 

SEC FILE NUMBER

000-55072

  NOTIFICATION OF LATE FILING

CUSIP NUMBER

 

 

(Check one): [_] Form 10-K [_] Form 20-F [_] Form 11-K [X] Form 10-Q [_] Form 10-D [_] Form N-CEN [_] Form N-CSR

 

  For Period Ended: March 31, 2024
   
  [_]  Transition Report on Form 10-K
  [_]  Transition Report on Form 20-F
  [_]  Transition Report on Form 11-K
  [_]  Transition Report on Form 10-Q
  For the Transition Period Ended:__________________________________

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

GlobeStar Therapeutics Corporation
Full Name of Registrant
 
 
Former Name if Applicable
 
719 Jadwin Avenue
Address of Principal Executive Office (Street and Number)
 
Richland, WA 99352
City, State and Zip Code

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

  (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

 

PART III — NARRATIVE

 

GlobeStar Therapeutics Corporation (the “Company”) is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Form 10-Q”). The Company plans to file its Form 10-Q within the additional 5 days allowed to complete and file the Form 10-Q.

 

PART IV — OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification

 

  James C. Katzaroff   509   531-1671
  (Name)   (Area Code)   (Telephone Number)

 

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

 

[X]  Yes [_]  No

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 

[_]  Yes [X]  No

 

  If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
   
   

 

  GlobeStar Therapeutics Corporation  
  (Name of Registrant as Specified in Charter)  

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date May 17, 2024   By /s/ James C. Katzaroff
        James C. Katzaroff, Chief Executive Officer

 

- 2 -

Globestar Therapeutics (PK) (USOTC:GSTC)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Globestar Therapeutics (PK).
Globestar Therapeutics (PK) (USOTC:GSTC)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Globestar Therapeutics (PK).